Perpetuum Ventures
Smedenstraat 20
2610 Antwerpen
BE
Perpetuum Ventures
Foundation date
18-01-2018
Sector
#Biotechnology - TherapeuticsSubsector
- #Therapeutics - Peptides
- #Therapeutics - Proteins
- #Therapeutics - Small molecules
- #Therapeutics - Vaccines
- #Pharma - Nucleic acid drugs
Therapeutic areas
- #Cardiovascular
- #Conditions originating in the perinatal period
- #Digestive system
- #Neoplasms / cancer / oncology
- #Respiratory system
- #Skin and subcutaneous tissue
PIONEERING PLANT SCIENCE.
Perpetuum is a biotech company that develops safe, sustainable plant-based therapeutics for the effective management and improvement of healthspan of people.
Our company focuses on four R&D platforms:
Plant cell extraction
Transient expression of recombinant proteins in plants
Dendritic nano adjuvants
Biopolymer scaffolds
Upcoming events
All events-
2211 '21
Translational Immunology
Event by: VIB -
2710 '21
New Horizons in Alzheimer's Disease
Event by: VIB -
1611 '21
DxPx Conference 2021
Event by: DxPx Conference
Latest news
More news-
reMYND’s ReS19-T program, managing calcium homeostasis for Alzheimer’s, has moved to MAD phase after demonstrating strong safety in SAD phase
Thursday October 21st 2021
Read more
-
Mithra announces Estelle® launch in Belgium
Thursday October 21st 2021
Read more
-
Biotalys awarded multi-year grant to develop new biological solutions for cowpea and other legumes
Wednesday October 20th 2021
Read more